Kümler, Iben <br/><br/>
Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene.  [electronic resource] 

 -  BMC cancer  Jun 2019 
 - 573 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>1471-2407 
<br/><br/><label>Standard No.: </label>10.1186/s12885-019-5788-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Biomarkers, Pharmacological<br/>Breast Neoplasms--diagnosis<br/>DNA Topoisomerases, Type I--genetics<br/>Drug Therapy, Combination<br/>Female<br/>Gene Dosage<br/>Humans<br/>Irinotecan--therapeutic use<br/>Middle Aged<br/>Predictive Value of Tests<br/>Prognosis<br/>Receptor, ErbB-2--metabolism<br/>Topoisomerase I Inhibitors--therapeutic use<br/>Trastuzumab--therapeutic use<br/>Treatment Outcome